Home › Colorectal Cancer › NCT06096688
Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction
Discovering New Targets for Hereditary and Sporadic Colorectal and Endometrial Cancer Risk Reduction
Who can join
Ages 18 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
The following eligibility criteria must be met as follows: 1. Age ≥ 18 years old. 2. One of the following must be met: 1. Diagnosis of a Hereditary Cancer Syndrome by positive genetic testing and/or clinical criteria to undergo an endoscopy procedure (esophagoduodenoscopy and/or colonoscopy/flexible sigmoidoscopy), or endometrial screening procedure (transvaginal ultrasound and/or hysteroscopy and/or endometrial biopsy), OR 2. Individuals coming to Weill-Cornell Medicine/NYPH to undergo an endoscopy procedure, transvaginal ultrasound, or hysteroscopy for average-risk (population-based) recommendation OR 3. Individuals diagnosed with colorectal cancer or endometrial cancer coming to Weill- Cornell Medicine/NYPH for surgical treatment OR 4. Individuals coming to Weill-Cornell Medicine/NYPH for care such as, but not limited to, diagnostic testing, clinic and/or treatment visit. 3. Willingness and ability to sign informed consent. 4. Ability to read/understand English, Spanish, and/or simplified Chinese.
About the study
The primary aim of this study is to collect and store data, tissue, and personal and family histories from patients being screened for colorectal cancer and/or endometrial cancer at NYPH and WCM for routine clinical care and to make these available for future use for molecular and mechanistic studies.
Sponsor: Weill Medical College of Cornell University · Participants: 1,120 · Started: May 29, 2019
Contact the study team
- Julie M Blander, PhD · Phone: 646-962-6741
- Melissa K Frey, MD, MS · Phone: 646-697-6621
Official record on ClinicalTrials.gov — NCT06096688
Locations in the U.S.
| New York | NYP/Weill Cornell Medicine, New York |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.